Nifty Microcap 250

Eureka Forbes has informed that the exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Catalyst Trusteeship.

The above information is a part of company’s filings submitted to BSE.

Viyash Scientific has informed that he Nomination and Remuneration Committee of the Company vide resolution passed by circulation on September 18, 2026, has approved the allotment of 11,07,309 equity shares of face value Rs. 2/- each, fully paid up, pursuant to the exercise of stock options under the Sequent Scientific Limited Employee Stock Option Plan 2020 (“Sequent ESOP 2020”) and the Viyash Scientific Limited Employee Stock Option Scheme 2026 (“Viyash ESOP 2026”), as detailed below: a. 9,26,333 equity shares at an exercise price of Rs. 86 per equity share to eligible optionees under Sequent ESOP 2020. b. 1,80,976 equity shares at an exercise price of Rs.101 per equity share to eligible optionees under Viyash ESOP 2026. The aforesaid equity shares shall rank pari passu in all respects with the existing equity shares of the Company. Consequent to the aforesaid allotment, the issued and paid-up equity share capital of the Company has increased from Rs. 88,10,40,722/- consisting of 44,05,20,361 Equity Shares of Rs. 2 each to Rs. 88,32,55,340/-, comprising of 44,16,27,670 Equity Shares of Rs. 2 each.

The above information is a part of company’s filings submitted to BSE.

Embassy Developments has informed that it enclosed Press release dated September 18, 2026, titled ‘Embassy Developments Reimagines Real Estate Marketing with 'Natural Intelligence'.

The above information is a part of company’s filings submitted to BSE.

Pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, Corona Remedies has informed that the officials of the Company will be meeting analysts / investors on Wednesday, September 23, 2026 at 2:00 pm organized by JP Morgan in Ahmedabad. Discussions will be based on publicly available information. No unpublished price sensitive information (UPSI) is intended to be discussed during the interactions. This intimation is also being made available on the website of the Company at www.coronaremedies.com. 

The above information is a part of company’s filings submitted to BSE.

KNR Constructions has that the Company is in receipt of order from Office of Commissioner of Income Tax – Appeals - Hyderabad-12 and the details as required under Regulation 30 of SEBI (LODR) Regulations, 2015 are enclosed.

The above information is a part of company’s filings submitted to BSE.